Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lyubomir T Vassilev

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Cell Cycle (Georgetown, Tex.)|March 9, 2004
Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeuticsLyubomir T Vassilev
Cell Cycle (Georgetown, Tex.)|December 19, 2006
Cell cycle synchronization at the G2/M phase border by reversible inhibition of CDK1Lyubomir T Vassilev
Trends in Molecular Medicine|November 28, 2006
MDM2 inhibitors for cancer therapyLyubomir T Vassilev
Journal of Medicinal Chemistry|July 8, 2005
p53 Activation by small molecules: application in oncologyLyubomir T Vassilev
Aging|February 17, 2010
Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3Baoying Huang, Lyubomir T Vassilev
Methods in Enzymology|December 13, 2005
High-throughput screening for inhibitors of the Cks1-Skp2 interactionKuo-Sen Huang, Lyubomir T Vassilev
Journal of Molecular Medicine (Berlin, Germany)|November 12, 2005
Targeting protein-protein interactions for cancer therapyDavid C Fry, Lyubomir T Vassilev
Methods in Enzymology|December 13, 2005
Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspectsDavid C Fry, Bradford Graves, Lyubomir T Vassilev
Molecular Cancer Research : MCR|September 10, 2009
Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cellsBaoying Huang, Dayanand Deo, Mingxuan Xia, et al.
Molecular Cancer Therapeutics|April 22, 2010
1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53Thelma Thompson, Michael Andreeff, George P Studzinski, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Cell Cycle (Georgetown, Tex.)|March 9, 2004
Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeuticsLyubomir T Vassilev
Cell Cycle (Georgetown, Tex.)|December 19, 2006
Cell cycle synchronization at the G2/M phase border by reversible inhibition of CDK1Lyubomir T Vassilev
Trends in Molecular Medicine|November 28, 2006
MDM2 inhibitors for cancer therapyLyubomir T Vassilev
Journal of Medicinal Chemistry|July 8, 2005
p53 Activation by small molecules: application in oncologyLyubomir T Vassilev
Aging|February 17, 2010
Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3Baoying Huang, Lyubomir T Vassilev
Methods in Enzymology|December 13, 2005
High-throughput screening for inhibitors of the Cks1-Skp2 interactionKuo-Sen Huang, Lyubomir T Vassilev
Journal of Molecular Medicine (Berlin, Germany)|November 12, 2005
Targeting protein-protein interactions for cancer therapyDavid C Fry, Lyubomir T Vassilev
Methods in Enzymology|December 13, 2005
Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspectsDavid C Fry, Bradford Graves, Lyubomir T Vassilev
Molecular Cancer Research : MCR|September 10, 2009
Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cellsBaoying Huang, Dayanand Deo, Mingxuan Xia, et al.
Molecular Cancer Therapeutics|April 22, 2010
1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53Thelma Thompson, Michael Andreeff, George P Studzinski, et al.
Pageof 6